Zhejiang Garden Bio-chemical High-tech Co Ltd
SZSE:300401

Watchlist Manager
Zhejiang Garden Bio-chemical High-tech Co Ltd Logo
Zhejiang Garden Bio-chemical High-tech Co Ltd
SZSE:300401
Watchlist
Price: 15.58 CNY
Market Cap: 8.5B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Zhejiang Garden Bio-chemical High-tech Co Ltd stock under the Base Case scenario is 12.37 CNY. Compared to the current market price of 15.58 CNY, Zhejiang Garden Bio-chemical High-tech Co Ltd is Overvalued by 21%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
12.37 CNY
Overvaluation 21%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.8
P/S
P/S
Price to Sales
6.8
vs History
44
vs Industry
20
Median 3Y
5.7
Median 5Y
6.6
Industry
2.4
Forward
4.3
More Details
26.9
P/E
P/E
Price to Earnings
26.9
vs History
30
vs Industry
17
Median 3Y
25.6
Median 5Y
24.3
Industry
20.5
Forward
19.1
More Details
17
P/OCF
P/OCF
Price to OCF
17
vs History
68
vs Industry
19
Median 3Y
24.7
Median 5Y
20.4
Industry
15.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
8
Median 3Y
5.9
Median 5Y
4.8
Industry
23.1
More Details
2.6
P/B
P/B
Price to Book Value
2.6
vs History
41
vs Industry
31
Median 3Y
2.5
Median 5Y
2.6
Industry
2
More Details
6.9
EV/S
EV/S
Enterprise Value to Sales
6.9
vs History
42
vs Industry
19
Median 3Y
5.7
Median 5Y
6.6
Industry
2.5
Forward
4.4
More Details
12.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
12.4
vs History
36
vs Industry
17
Median 3Y
8.8
Median 5Y
10.6
Industry
4.9
More Details
23.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
23.2
vs History
23
vs Industry
14
Median 3Y
21.7
Median 5Y
20.6
Industry
12.3
Forward
7.2
More Details
23.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
23.2
vs History
23
vs Industry
17
Median 3Y
21.7
Median 5Y
20.6
Industry
15.5
Forward
16
More Details
17.2
EV/OCF
EV/OCF
Enterprise Value to OCF
17.2
vs History
61
vs Industry
18
Median 3Y
23.8
Median 5Y
19.7
Industry
14.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-96.3
Median 5Y
-57.4
Industry
17.5
More Details
2.2
EV/IC
EV/IC
Enterprise Value to IC
2.2
vs History
69
vs Industry
33
Median 3Y
2.2
Median 5Y
2.6
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Zhejiang Garden Bio-chemical High-tech Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Zhejiang Garden Bio-chemical High-tech Co Ltd
SZSE:300401
8.5B CNY 6.8 26.9 23.2 23.2
US
Eli Lilly and Co
NYSE:LLY
716.1B USD 14.6 64.5 34.7 37.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
370.8B USD 4.2 17 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.4 12.8 14.6
CH
Roche Holding AG
SIX:ROG
208.3B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
179.6B CHF 4 16.6 9.8 13.1
UK
AstraZeneca PLC
LSE:AZN
159.3B GBP 3.8 27 130.3 196.5
US
Merck & Co Inc
NYSE:MRK
202.4B USD 3.2 11.6 8.6 10.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
131.3B USD 2.1 16.7 7.2 10.2
P/E Multiple
Earnings Growth PEG
CN
Zhejiang Garden Bio-chemical High-tech Co Ltd
SZSE:300401
Average P/E: 25
26.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
64.5
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.4
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
16.6
17%
1
UK
AstraZeneca PLC
LSE:AZN
27
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.6
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.7
29%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Zhejiang Garden Bio-chemical High-tech Co Ltd
SZSE:300401
Average EV/EBIT: 1 699.2
23.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.8
CH
Novartis AG
SIX:NOVN
13.1
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.5
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.5
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 254,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.